AstraZeneca (AZ) has appointed Iskra Reic as executive vice president, international, with the role encompassing the company’s operations in China, Asia, Eurasia, the Middle East, Africa, Latin America, Australia and New Zealand.
Reic first joined AZ over two decades ago and has since held a variety of leadership roles during her time at the company, including head of specialty care for Central and Eastern Europe, the Middle East and Africa, area vice president of Russia and Eurasia, and executive vice president for Europe and Canada.
She has most recently been serving as executive vice president of AZ’s vaccines and immune therapies unit. In this role, she has been responsible for the early and late-stage development of the unit’s pipeline and portfolio, including COVID-19 and respiratory syncytial virus vaccines and monoclonal antibodies, strategic partnerships and acquisitions, medical affairs and commercial operations.
She is also currently a member of myTomorrows’ board of directors, as well as a member of the Steering Committee of the Partnership for Health System Sustainability and Resilience.
Reic said: “It is a privilege to lead this broad, diverse and innovative region… I look forward to working with our partners, stakeholders and colleagues to improve the lives of millions of people around the world with our… medicines and vaccines.”
Also commenting on the appointment, AZ’s chief executive officer, Pascal Soriot, said: “Iskra is a highly accomplished leader with extensive international experience across multiple disciplines and a track record of improving patient access to our… medicines. Her experience building partnerships will be invaluable in taking the fast-growing international region forward.”